Literature DB >> 25546769

Adverse effects of immunoglobulin G therapy: thromboembolism and haemolysis.

F A Bonilla1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25546769      PMCID： PMC4285498          DOI： 10.1111/cei.12518

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  10 in total

1.  Anti-A and anti-B haemagglutinin levels in intravenous immunoglobulins: are they on the rise? A comparison of four different analysis methods and six products.

Authors:  C L Bellac; D Polatti; T Hottiger; P Girard; M Sänger; M Gilgen
Journal:  Biologicals       Date:  2013-12-08       Impact factor: 1.856

2.  Hyperimmune globulins and same-day thrombotic adverse events as recorded in a large healthcare database during 2008-2011.

Authors:  Mikhail Menis; Gayathri Sridhar; Nandini Selvam; Mikhail V Ovanesov; Hozefa A Divan; Yideng Liang; Dorothy Scott; Basil Golding; Richard Forshee; Robert Ball; Steven A Anderson; Hector S Izurieta
Journal:  Am J Hematol       Date:  2013-09-12       Impact factor: 10.047

3.  Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010.

Authors:  Gregory W Daniel; Mikhail Menis; Gayathri Sridhar; Dorothy Scott; Anna E Wallace; Mikhail V Ovanesov; Basil Golding; Steven A Anderson; Jay Epstein; David Martin; Robert Ball; Hector S Izurieta
Journal:  Transfusion       Date:  2012-03-12       Impact factor: 3.157

4.  Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: a two-year study.

Authors:  Yusuf A Rajabally; David A Kearney
Journal:  J Neurol Sci       Date:  2011-06-15       Impact factor: 3.181

5.  Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients.

Authors:  R K Woodruff; A P Grigg; F C Firkin; I L Smith
Journal:  Lancet       Date:  1986-07-26       Impact factor: 79.321

Review 6.  Adverse effects of human immunoglobulin therapy.

Authors:  E Richard Stiehm
Journal:  Transfus Med Rev       Date:  2013-07-06

7.  Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products.

Authors:  M Etscheid; S Breitner-Ruddock; S Gross; A Hunfeld; R Seitz; J Dodt
Journal:  Vox Sang       Date:  2011-05-05       Impact factor: 2.144

Review 8.  Intravenous immunoglobulin-induced haemolysis: a case report and review of the literature.

Authors:  M J Desborough; J Miller; S J Thorpe; M F Murphy; S A Misbah
Journal:  Transfus Med       Date:  2013-10-25       Impact factor: 2.019

9.  Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases.

Authors:  Roberta Berard; Blair Whittemore; Rosie Scuccimarri
Journal:  Pediatr Rheumatol Online J       Date:  2012-04-16       Impact factor: 3.054

10.  Isoagglutinin Reduction in Human Immunoglobulin Products by Donor Screening.

Authors:  Brigitte Siani; Katharina Willimann; Sandra Wymann; Adriano A Marques; Eleonora Widmer
Journal:  Biol Ther       Date:  2014-05-20
  10 in total
  3 in total

1.  Interplay between Myasthenia Gravis and Severe COVID-19 Infection: The Missing Links.

Authors:  Shalendra Singh; Praneet Vashishtha; Nipun Gupta; Ravi Wadke; Priya Taank
Journal:  Indian J Crit Care Med       Date:  2022-02

2.  II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies.

Authors:  Ekaterini Simões Goudouris; Almerinda Maria do Rego Silva; Aluce Loureiro Ouricuri; Anete Sevciovic Grumach; Antonio Condino-Neto; Beatriz Tavares Costa-Carvalho; Carolina Cardoso Prando; Cristina Maria Kokron; Dewton de Moraes Vasconcelos; Fabíola Scancetti Tavares; Gesmar Rodrigues Silva Segundo; Irma Cecília Barreto; Mayra de Barros Dorna; Myrthes Anna Barros; Wilma Carvalho Neves Forte
Journal:  Einstein (Sao Paulo)       Date:  2017

Review 3.  Adverse Effects of Immunoglobulin Therapy.

Authors:  Yi Guo; Xin Tian; Xuefeng Wang; Zheng Xiao
Journal:  Front Immunol       Date:  2018-06-08       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.